Htx-001

Phase 1

HHaya Therapeutics, Inc.

Htx-001 is one of 15 therapeutic programs targeting Hypertrophic Cardiomyopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hypertrophic CardiomyopathyRecruiting

Hypertrophic CardiomyopathyPhase 1

Recruiting

Competition

Competitive Landscape

20 competitors in Hypertrophic Cardiomyopathy

#DrugCompanyPhaseTrials

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

13 2

Aldactone

Pfizer

Approved

2 3

Lexiscan

Astellas

Approved

1 4

Adenocard

Astellas

Approved

1 5

Zebeta

Teva

Approved

1 6

Bayer Aspirin

Calan

1 8

Cardizem

BBausch Health Americas, Inc.

Approved

1 9

Acetadote

AArbor Pharmaceuticals, Inc.

Xarelto

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hypertrophic Cardiomyopathy

NCT07867288

Clinical

Trials by Indication[1]

Hypertrophic Cardiomyopathy1 trial

A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)

Recruiting·HHaya Therapeutics, Inc.·Phase 1·NCT07867288·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Htx-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Htx-001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Haya Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHaya Therapeutics, Inc.

Htx-001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hypertrophic Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News